Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
ICI resistance
IDO inhibitors
PI3K/ALK pathway
adenosine pathway
antiangiogenic
immunotherapy
macrophages
metabolism
microbiome
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
21 Jun 2020
21 Jun 2020
Historique:
received:
25
05
2020
revised:
15
06
2020
accepted:
19
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
10
2
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have changed therapeutic algorithms in several malignancies, although intrinsic and secondary resistance is still an issue. In this context, the dysregulation of immuno-metabolism plays a leading role both in the tumor microenvironment (TME) and at the host level. In this review, we summarize the most important immune-metabolic factors and how they could be exploited therapeutically. At the cellular level, an increased concentration of extracellular adenosine as well as the depletion of tryptophan and uncontrolled activation of the PI3K/AKT pathway induces an immune-tolerant TME, reducing the response to ICIs. Moreover, aberrant angiogenesis induces a hypoxic environment by recruiting VEGF, T
Identifiants
pubmed: 32575899
pii: ijms21124414
doi: 10.3390/ijms21124414
pmc: PMC7352562
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Adv Exp Med Biol. 2020;1219:93-107
pubmed: 32130695
Oncotarget. 2016 Jun 21;7(25):37762-37772
pubmed: 27192116
JAMA Oncol. 2019 Apr 1;5(4):529-536
pubmed: 30605213
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Cancer Discov. 2014 Aug;4(8):879-88
pubmed: 25035124
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Immunotherapy. 2019 Jun;11(8):677-689
pubmed: 31088236
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
FASEB J. 2006 Jan;20(1):187-9
pubmed: 16280366
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19961-6
pubmed: 21041655
Am J Clin Nutr. 2014 May;99(5):999-1005
pubmed: 24572565
Cancer Causes Control. 2014 Oct;25(10):1407-18
pubmed: 25037235
Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):380-391
pubmed: 29685424
Lancet Oncol. 2018 Aug;19(8):e379
pubmed: 30102229
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Cancer Immunol Res. 2014 Nov;2(11):1080-9
pubmed: 25080445
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
N Engl J Med. 2018 Nov 01;379(18):1711-1721
pubmed: 30380386
Immunol Lett. 2019 Jan;205:9-15
pubmed: 29702147
Cancer Immunol Res. 2020 Jan;8(1):131-145
pubmed: 31771984
Lancet Respir Med. 2019 May;7(5):387-401
pubmed: 30922878
Immunity. 2005 May;22(5):633-42
pubmed: 15894280
Nat Rev Cancer. 2018 Dec;18(12):744-757
pubmed: 30425336
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
FASEB J. 2018 Feb;32(2):829-837
pubmed: 28982732
J Thorac Oncol. 2019 Jan;14(1):124-129
pubmed: 30138764
Curr Oncol Rep. 2016 Sep;18(9):56
pubmed: 27475805
Clin Cancer Res. 2017 Jul 1;23(13):3269-3276
pubmed: 28053021
Nat Med. 2005 Mar;11(3):312-9
pubmed: 15711557
Clin Cancer Res. 2013 Oct 15;19(20):5626-35
pubmed: 23983257
Cell. 2016 Apr 7;165(2):276-87
pubmed: 27058662
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Gut. 2016 May;65(5):749-56
pubmed: 26719299
Sci Transl Med. 2015 Mar 4;7(277):277ra30
pubmed: 25739764
Urology. 2006 Oct;68(4):741-6
pubmed: 17070345
Lancet Oncol. 2017 Dec;18(12):e731-e741
pubmed: 29208439
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
J Hematol Oncol. 2018 Aug 2;11(1):100
pubmed: 30068361
J Immunol. 2006 Nov 15;177(10):6598-602
pubmed: 17082571
Cancer Res. 2006 Aug 1;66(15):7758-65
pubmed: 16885379
Biol Blood Marrow Transplant. 2010 Oct;16(10):1442-50
pubmed: 20412867
Front Oncol. 2020 Jan 22;9:1380
pubmed: 32038992
Cancer Causes Control. 2014 Nov;25(11):1489-502
pubmed: 25070668
J Natl Cancer Inst. 2013 Dec 18;105(24):1862-70
pubmed: 24285872
J Immunol. 2015 Oct 15;195(8):3880-9
pubmed: 26355151
Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
pubmed: 20379207
J Immunother Cancer. 2019 Aug 19;7(1):222
pubmed: 31426863
Annu Rev Immunol. 2013;31:675-704
pubmed: 23330955
Ann Oncol. 2020 Apr;31(4):525-531
pubmed: 32115349
Adv Exp Med Biol. 2020;1244:51-68
pubmed: 32301010
Clin Cancer Res. 2006 Feb 15;12(4):1144-51
pubmed: 16489067
Nat Commun. 2020 Apr 14;11(1):1779
pubmed: 32286310
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
Cancer J. 2018 Jul/Aug;24(4):193-204
pubmed: 30119083
Lancet Oncol. 2018 Jun;19(6):716-717
pubmed: 29778735
Cancer Med. 2019 Jul;8(8):4023-4031
pubmed: 31165589
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Cancer Cell. 2016 Sep 12;30(3):391-403
pubmed: 27622332
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Oncoimmunology. 2017 Jun 8;6(9):e1326442
pubmed: 28932632
Am J Hematol. 2013 Aug;88(8):642-6
pubmed: 23619915
Oncoimmunology. 2019 Mar 16;8(5):e1581556
pubmed: 31069145
Semin Immunopathol. 2019 Jan;41(1):41-48
pubmed: 30203227
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
N Engl J Med. 2019 Jan 31;380(5):497-498
pubmed: 30699313
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Cancer Immunol Immunother. 2011 Oct;60(10):1405-18
pubmed: 21638125
Nat Med. 2019 Nov;25(11):1715-1720
pubmed: 31700181
Cell. 2015 Sep 10;162(6):1217-28
pubmed: 26321681
Clin Cancer Res. 2019 Jun 1;25(11):3220-3228
pubmed: 30770348
Cancer Immunol Res. 2015 Feb;3(2):161-72
pubmed: 25271151
Med Sci (Basel). 2019 Jan 22;7(2):
pubmed: 30678257
Front Immunol. 2019 Jul 30;10:1801
pubmed: 31417567
Arch Esp Urol. 2018 Sep;71(8):685-695
pubmed: 30319128
Eur J Cancer. 2017 May;76:167-182
pubmed: 28324751
Nature. 2014 Jun 19;510(7505):407-411
pubmed: 24919154
Biol Blood Marrow Transplant. 2006 May;12(5):541-51
pubmed: 16635789
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Urol. 2018 May;199(5):1129-1142
pubmed: 29113841
J Clin Med. 2018 Dec 12;7(12):
pubmed: 30545122
Cell. 2017 May 4;169(4):570-586
pubmed: 28475890
Clin Cancer Res. 2008 Jun 1;14(11):3372-9
pubmed: 18519766
J Surg Res. 2015 Dec;199(2):378-85
pubmed: 26115811
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Semin Cancer Biol. 2018 Feb;48:91-103
pubmed: 28467889
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Oncoimmunology. 2018 Aug 20;7(11):e1507670
pubmed: 30377571
Science. 2012 Jun 8;336(6086):1268-73
pubmed: 22674334
J Pain Symptom Manage. 2018 Jun;55(6):1500-1508
pubmed: 29496534
Front Oncol. 2018 Oct 04;8:423
pubmed: 30338242
Blood. 1998 Dec 1;92(11):4150-66
pubmed: 9834220
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
PLoS One. 2013 Jun 13;8(6):e65821
pubmed: 23785454
Front Oncol. 2018 Jan 23;8:3
pubmed: 29410946
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
J Immunol. 2003 Aug 15;171(4):1652-5
pubmed: 12902462
Nat Immunol. 2013 Oct;14(10):1064-72
pubmed: 23955661
Immunotherapy. 2018 Jul;10(9):733-736
pubmed: 30008261
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Int J Cancer. 2018 Jul 1;143(1):45-51
pubmed: 29424425
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S
pubmed: 15465796
Br J Dermatol. 2014 Nov;171(5):987-95
pubmed: 24814041
Cell. 2006 Feb 24;124(4):837-48
pubmed: 16497592
Oncotarget. 2017 Nov 1;8(59):99336-99346
pubmed: 29245905
J Exp Med. 2013 Jul 1;210(7):1389-402
pubmed: 23752227
Clin Dev Immunol. 2011;2011:565187
pubmed: 22162712
J Exp Med. 2019 Jun 3;216(6):1244-1254
pubmed: 31068379
Nat Rev Cancer. 2017 Nov 22;17(12):765
pubmed: 29162946
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Pharmacol Rev. 2011 Mar;63(1):1-34
pubmed: 21303899
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Sci Immunol. 2020 Jan 3;5(43):
pubmed: 31901075
J Evid Based Med. 2019 Nov;12(4):253-262
pubmed: 31430052
Science. 1998 Aug 21;281(5380):1191-3
pubmed: 9712583
Anticancer Res. 2017 Jun;37(6):3195-3200
pubmed: 28551664
Molecules. 2019 Sep 04;24(18):
pubmed: 31487832
Clin Pharmacokinet. 2010 Oct;49(10):633-59
pubmed: 20818831
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Immunology. 2009 Sep;128(1 Suppl):e728-37
pubmed: 19740334
Clin Dev Immunol. 2011;2011:469135
pubmed: 22110525
Cancer Med. 2016 Apr;5(4):665-75
pubmed: 26811258
J Immunol. 2009 Nov 15;183(10):6095-101
pubmed: 19841171
Ann Oncol. 2019 Dec 1;30(12):1914-1924
pubmed: 31613312
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Cancer Immunol Res. 2014 Jul;2(7):632-42
pubmed: 24838938
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585
FEBS J. 2018 Feb;285(4):763-776
pubmed: 28941174
Clin Cancer Res. 2008 Apr 15;14(8):2310-7
pubmed: 18413819
Future Oncol. 2020 Jan;16(2):4359-4368
pubmed: 31823654
Front Immunol. 2013 Feb 01;4:20
pubmed: 23378844
Oncotarget. 2018 May 11;9(36):24381-24390
pubmed: 29849947